Chemkart India Ltd
Incorporated in 2020, Chemkart India Limited, based in Mumbai, is a B2B nutraceutical ingredient distributor and processor.[1]
- Market Cap ₹ 274 Cr.
- Current Price ₹ 226
- High / Low ₹ 262 / 190
- Stock P/E 11.1
- Book Value ₹
- Dividend Yield 0.00 %
- ROCE 62.0 %
- ROE 60.2 %
- Face Value ₹ 10.0
Pros
- Company has a good return on equity (ROE) track record: 3 Years ROE 63.3%
Cons
- Working capital days have increased from 57.1 days to 82.1 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Fast Moving Consumer Goods Fast Moving Consumer Goods Food Products Other Food Products
Part of BSE SME IPO
Quarterly Results
Standalone Figures in Rs. Crores / View Consolidated
| Operating Profit |
| OPM % |
| Interest |
| Depreciation |
| Profit before tax |
| Tax % |
| EPS in Rs |
| Raw PDF |
Profit & Loss
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| 87 | 131 | 132 | 203 | |
| 80 | 120 | 112 | 170 | |
| Operating Profit | 7 | 11 | 20 | 33 |
| OPM % | 8% | 9% | 15% | 16% |
| 0 | 0 | 1 | 2 | |
| Interest | 0 | 1 | 1 | 2 |
| Depreciation | 0 | 0 | 0 | 1 |
| Profit before tax | 7 | 11 | 19 | 33 |
| Tax % | 26% | 28% | 28% | 24% |
| 5 | 8 | 14 | 25 | |
| EPS in Rs | 40.46 | 58.73 | 102.73 | 26.06 |
| Dividend Payout % | 0% | 0% | 0% | 0% |
| Compounded Sales Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 33% |
| TTM: | 54% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 65% |
| TTM: | 78% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| 1 Year: | % |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | 63% |
| Last Year: | 60% |
Balance Sheet
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Equity Capital | 1 | 1 | 1 | 10 |
| Reserves | 5 | 13 | 27 | 44 |
| 2 | 11 | 12 | 17 | |
| 17 | 15 | 13 | 16 | |
| Total Liabilities | 26 | 40 | 54 | 86 |
| 1 | 6 | 5 | 5 | |
| CWIP | 0 | 0 | 0 | 0 |
| Investments | 0 | 0 | 0 | 0 |
| 25 | 35 | 49 | 81 | |
| Total Assets | 26 | 40 | 54 | 86 |
Cash Flows
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| -0 | 5 | -2 | -3 | |
| -1 | -5 | -0 | -0 | |
| 1 | 1 | 3 | 6 | |
| Net Cash Flow | -0 | 0 | -0 | 3 |
Ratios
Standalone Figures in Rs. Crores / View Consolidated
| Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
|---|---|---|---|---|
| Debtor Days | 81 | 62 | 88 | 83 |
| Inventory Days | 10 | 25 | 27 | 50 |
| Days Payable | 65 | 37 | 35 | 26 |
| Cash Conversion Cycle | 25 | 50 | 81 | 107 |
| Working Capital Days | 23 | 25 | 64 | 82 |
| ROCE % | 67% | 62% | 62% |
Documents
Announcements
-
Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations, 2018
13 Oct - Certificate under Regulation 74(5) of SEBI (DP) Regulations 2018 for the Quarter ended 30th September 2025.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
30 Sep - Virtual one-on-one investor meeting with Nuvama Wealth on 06-Oct-2025 at 4:00 PM.
-
Announcement under Regulation 30 (LODR)-Analyst / Investor Meet - Intimation
22 Sep - Management to attend Arihant (25 Sep 2025, virtual) and SMC SAMPARK (26 Sep 2025, physical) conferences.
-
Closure of Trading Window
22 Sep - Trading window closed from 01-Oct-2025 until 48 hours after H1 FY2025 results (30-Sep-2025).
- Announcement under Regulation 30 (LODR)-Investor Presentation 11 Sep
Annual reports
No data available.
Concalls
-
Sep 2025TranscriptNotesPPT
Business Segment[1]
a) Trading Business:(97% of H1FY25 revenue)[2]
The company sources a wide range of nutraceutical ingredients—such as amino acids, vitamins, herbal extracts, and proteins—mainly through imports, and supplies them to B2B clients for manufacturing finished supplements.